Publicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (12)

2024

  1. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

2023

  1. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  2. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

2022

  1. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  2. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

  3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

  4. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

  5. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

  2. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

    Bone Marrow Transplantation, Vol. 55, Núm. 3, pp. 641-648

2019

  1. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2017

  1. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109